左卡尼汀联合1,6-二磷酸果糖治疗小儿病毒性心肌炎的临床疗效分析

目的探讨左卡尼汀(Levocarnitine)联合1,6-二磷酸果糖(1,6-diphosphate,1,6-Dip)治疗小儿病毒性心肌炎(pediatric viral myocarditis,PVM)临床疗效及安全性。方法对2011年3月年至2013年11月我科收治的病毒性心肌炎患儿66例进行回顾性分析,其中在常规治疗(休息、维生素)基础上联合1,6-Dip者30例作为对照组,在基础治疗联合1,6-Dip及左卡尼汀组36例作为试验组。治疗2周,比较两组患儿的临床疗效及不良反应。结果治疗2周后试验组与对照组临床总有效率分别为94.4%和70.0%,试验组显著高于对照组(P<0.05);与治疗前相比,治疗后两组患儿心肌酶均显著下降(P<0.05),但试验组下降程度更为明显(P<0.05);试验组治疗期间发生恶心呕吐1例,无其他不良反应。结论左卡尼汀联合1,6-二磷酸果糖治疗小儿病毒性心肌炎临床疗效确切,安全有效。

Clinical Efficacy of Levocarnitine Combined with 1, 6-Diphosphate in the Treatment of Pediatric Viral Myocarditis

Objective To evaluate the clinical efficacy of Levocarnitine combined with 1, 6-diphosphate（1, 6-Dip） in the treatment of pediatric viral myocarditis（PVM）. Methods 66 cases of pediatric viral myocarditis in our department from March 2011 to November 2013were analyzed retrospectively. 30 cases of routine therapy combined with 1, 6-Dip were set as the control group, while 30 cases of routine therapy combined with 1, 6-Dip and Levocarnitine were set as the experiment group. After two weeks of treatment, the clinical efficacy and adverse reactions were compared between the two groups. Results After two weeks of treatment, the total effective rate was 94.4% of the experiment group, significantly higher than 70.0% of the control group（P 0.05）. Cardiac enzymes significantly decreased in both groups after treatment（both P 0.05）, but the decline degree of the experiment group was more significant（P 0.05）. One case of nausea and vomiting occurred in the experimental group. Conclusions Levocarnitine combined with 1, 6-diphosphate in the treatment of pediatric viral myocarditis is effective and safe.